Utility of pre-treatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio as prognostic factors in breast cancer

C-H Koh, N Bhoo-Pathy, K-L Ng, R S Jabir, G-H Tan, M-H See, S Jamaris, N A Taib, C-H Koh, N Bhoo-Pathy, K-L Ng, R S Jabir, G-H Tan, M-H See, S Jamaris, N A Taib

Abstract

Background: Peripheral blood-derived inflammation-based scores such as the neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) have recently been proposed as prognostic markers in solid tumours. Although evidence to support these markers as unfavourable prognostic factors is more compelling in gastrointestinal cancers, very little is known of their impact on breast cancer. We investigated the association between the NLR and PLR, and overall survival after breast cancer.

Methods: Data from the University of Malaya Medical Centre Breast Cancer Registry was used. Of 2059 consecutive patients diagnosed from 2000 to 2008, we included 1435 patients with an available pre-treatment differential blood count (∼70%). Patients were stratified into quintiles of the NLR/PLR. Multivariable Cox regression was used to determine the independent prognostic significances of the NLR/PLR.

Results: Compared with the first quintile of the NLR, women in quintile 5 were younger, had bigger tumours, nodal involvement, distant metastases and higher tumour grades. Higher NLR quintiles were significantly associated with poorer survival with a 5-year relative survival ratio (RSR) of 76.4% (95% CI: 69.6-82.1%) in quintile 1, 79.4% (95% CI: 74.4-83.7%) in quintile 2, 72.1% (95% CI: 66.3-77.3%) in quintile 3, 65.6% (95% CI: 59.8-70.8%) in quintile 4 and 51.1% (95% CI: 43.3-58.5%) in quintile 5. Following adjustment for demography, tumour characteristics, treatment and the PLR, the adjusted hazard ratio (HR) for quintile 5 vs quintile 1 was 1.50 (95% CI: 1.08-1.63); Ptrend=0.004. Results were unchanged when the NLR was analysed as a dichotomous variable using different cutoff points. Although patients in PLR quintile 5 had lower survival than in quintile 1 (5-year RSR: 53.2% (95% CI: 46.9-59.2%) vs 77.0% (95% CI: 70.9-82.2%)), this association was not significant after multivariable adjustment. However, a PLR >185 was significantly associated with poorer survival; adjusted HR: 1.25 (95% CI: 1.04-1.52).

Conclusions: Both the NLR and PLR are independently associated with an increased risk of mortality in breast cancer. Their added value in the prognostication of breast cancer in clinical practice warrants investigation.

Figures

Figure 1
Figure 1
Cumulative relative survival ratio by quintiles of neutrophil–lymphocyte ratio in 1435 Asian women with breast cancer.
Figure 2
Figure 2
Cumulative relative survival ratio by quintiles of platelet–lymphocyte ratio in 1435 Asian women with breast cancer.

References

    1. Azab B, Bhatt VR, Phookan J, Murukutla S, Kohn N, Terjanian T, Widmann WD (2012) Usefulness of the neutrophil-to-lymphocyte ratio in predicting short- and long-term mortality in breast cancer patients. Ann Surg Oncol 19: 217–224.
    1. Azab B, Shah N, Radbel J, Tan P, Bhatt V, Vonfrolio S, Habeshy A, Picon A, Bloom S (2013) Pretreatment neutrophil/lymphocyte ratio is superior to platelet/lymphocyte ratio as a predictor of long-term mortality in breast cancer patients. Med Oncol 30: 432.
    1. Bambace NM, Holmes CE (2011) The platelet contribution to cancer progression. J Thromb Haemost 9: 237–249.
    1. Chiang S-F, Hung H-Y, Tang R, Changchien CR, Chen J-S, You Y-T, Chiang J-M, Lin J-R (2012) Can neutrophil-to-lymphocyte ratio predict the survival of colorectal cancer patients who have received curative surgery electively? Int J Colorectal Dis 27: 1347–1357.
    1. Cihan YB, Arslan A, Cetindag MF, Mutlu H (2014) Lack of prognostic value of blood parameters in patients receiving adjuvant radiotherapy for breast cancer. Asian Pac J Cancer Prev 15: 4225–4231.
    1. Clarke C a, Glaser SL, West DW, Ereman RR, Erdmann CA, Barlow JM, Wrensch MR (2002) Breast cancer incidence and mortality trends in an affluent population: Marin County, California, USA, 1990-1999. Breast Cancer Res. 4: R13.
    1. Coleman MP, Quaresma M, Berrino F, Lutz J-M, De Angelis R, Capocaccia R, Baili P, Rachet B, Gatta G, Hakulinen T, Micheli A, Sant M, Weir HK, Elwood JM, Tsukuma H, Koifman SE, Silva GA, Francisci S, Santaquilani M, Verdecchia A, Storm HH, Young JL (2008) Cancer survival in five continents: a worldwide population-based study (CONCORD). Lancet Oncol 9: 730–756.
    1. Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420: 860–867.
    1. DeNardo DG, Coussens LM (2007) Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res 9: 212.
    1. Dickman PW, Sloggett A, Hills M, Hakulinen T (2004) Regression models for relative survival. Stat Med 23: 51–64.
    1. Dirican A, Kucukzeybek BB, Alacacioglu A, Kucukzeybek Y, Erten C, Varol U, Somali I, Demir L, Bayoglu IV, Yildiz Y, Akyol M, Koyuncu B, Coban E, Ulger E, Unay FC, Tarhan MO (2014) Do the derived neutrophil to lymphocyte ratio and the neutrophil to lymphocyte ratio predict prognosis in breast cancer? Int J Clin Oncol 20: 70–81.
    1. Gregory AD, Houghton A M (2011) Tumor-associated neutrophils: new targets for cancer therapy. Cancer Res 71: 2411–2416.
    1. Guthrie GJK, Charles KA, Roxburgh CSD, Horgan PG, McMillan DC, Clarke SJ (2013) The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. Crit Rev Oncol Hematol 88: 218–230.
    1. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144: 646–674.
    1. Krenn-Pilko S, Langsenlehner U, Thurner E-M, Stojakovic T, Pichler M, Gerger A, Kapp KS, Langsenlehner T (2014) The elevated preoperative platelet-to-lymphocyte ratio predicts poor prognosis in breast cancer patients. Br J Cancer 110: 2524–2530.
    1. Lal I, Dittus K, Holmes CE (2013) Platelets, coagulation and fibrinolysis in breast cancer progression. Breast Cancer Res 15: 207–218.
    1. De Larco JE, Wuertz BRK, Furcht LT (2004) The potential role of neutrophils in promoting the metastatic phenotype of tumors releasing interleukin-8. Clin Cancer Res 10: 4895–4900.
    1. Levine MN, Browman GP, Gent M, Roberts R, Goodyear M (1991) When is a prognostic factor useful?: A guide for the perplexed. J Clin Oncol 9: 348–356.
    1. Li M-X, Liu X-M, Zhang X-F, Zhang J-F, Wang W-L, Zhu Y, Dong J, Cheng J-W, Liu Z-W, Ma L, Lv Y (2014) Prognostic role of neutrophil-to-lymphocyte ratio in colorectal cancer: a systematic review and meta-analysis. Int J Cancer 134: 2403–2413.
    1. Limaye AR, Clark V, Soldevila-Pico C, Morelli G, Suman A, Firpi R, Nelson DR, Cabrera R (2013) Neutrophil-lymphocyte ratio predicts overall and recurrence-free survival after liver transplantation for hepatocellular carcinoma. Hepatol Res 43: 757–764.
    1. Mahmoud SM a, Paish EC, Powe DG, Macmillan RD, Grainge MJ, Lee AHS, Ellis IO, Green AR (2011) Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol 29: 1949–1955.
    1. Nakano K, Hosoda M, Yamamoto M, Yamashita H (2014) Prognostic significance of pre-treatment neutrophil: lymphocyte ratio in japanese patients with breast cancer. Anticancer Res 34: 3819–3824.
    1. Noh H, Eomm M, Han A (2013) Usefulness of pretreatment neutrophil to lymphocyte ratio in predicting disease-specific survival in breast cancer patients. J Breast Cancer 16: 55–59.
    1. Pathy NB, Yip CH, Taib NA, Hartman M, Saxena N, Iau P, Bulgiba AM, Lee SC, Lim SE, Wong JEL, Verkooijen HM (2011) Breast cancer in a multi-ethnic Asian setting: results from the Singapore-Malaysia hospital-based breast cancer registry. Breast 20(Suppl 2): S75–S80.
    1. Proctor MJ, Morrison DS, Talwar D, Balmer SM, Fletcher CD, O'Reilly DSJ, Foulis AK, Horgan PG, McMillan DC (2011) A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study. Eur J Cancer 47: 2633–2641.
    1. Roxburgh CSD, McMillan DC (2010) Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol 6: 149–163.
    1. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, Schreiber RD (2001) IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410: 1107–1111.
    1. Sharaiha RZ, Halazun KJ, Mirza F, Port JL, Lee PC, Neugut AI, Altorki NK, Abrams JA (2011) Elevated preoperative neutrophil:lymphocyte ratio as a predictor of postoperative disease recurrence in esophageal cancer. Ann Surg Oncol 18: 3362–3369.
    1. Shimada H, Takiguchi N, Kainuma O, Soda H, Ikeda A, Cho A, Miyazaki A, Gunji H, Yamamoto H, Nagata M (2010) High preoperative neutrophil-lymphocyte ratio predicts poor survival in patients with gastric cancer. Gastric Cancer 13: 170–176.
    1. Stotz M, Gerger A, Eisner F, Szkandera J, Loibner H, Ress AL, Kornprat P, AlZoughbi W, Seggewies FS, Lackner C, Stojakovic T, Samonigg H, Hoefler G, Pichler M (2013) Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer. Br J Cancer 109: 416–421.
    1. Templeton AJ, Ace O, McNamara MG, Al-Mubarak M, Vera-Badillo FE, Hermanns T, Seruga B, Ocaña A, Tannock IF, Amir E (2014. a) Prognostic role of platelet to lymphocyte ratio in solid tumors: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev 23: 1204–1212.
    1. Templeton AJ, McNamara MG, Seruga B, Vera-Badillo FE, Aneja P, Ocaña A, Leibowitz-Amit R, Sonpavde G, Knox JJ, Tran B, Tannock IF, Amir E (2014. b) Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: A systematic review and meta-analysis. J Natl Cancer Inst 106: 1–11.
    1. Voutsadakis IA (2014) Thrombocytosis as a prognostic marker in gastrointestinal cancers. World J Gastrointest Oncol 6: 34–40.
    1. Walsh SR, Cook EJ, Goulder F, Justin TA, Keeling NJ (2005) Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol 91: 181–184.
    1. Xu A, Huang L, Zhu L, Wei Z (2014) Significance of peripheral neutrophil-lymphocyte ratio among gastric cancer patients and construction of a treatment-predictive model: a study based on 1131 cases. Am J Cancer Res 4: 189–195.
    1. Yao M, Liu Y, Jin H, Liu X, Lv K, Wei H, Du C, Wang S, Wei B, Fu P (2014) Prognostic value of preoperative inflammatory markers in Chinese patients with breast cancer. Onco Targets Ther 7: 1743–1752.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다